Disease · MONDO_0005170
Comparisons in its trials24
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 24
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Futibatinib (Cohort A) vs Futibatinib (Cohort B): deaths from any cause | 54 of 87 | 24 of 28 | 115 | NCT04189445 | Trial comparisons |
| Futibatinib (Cohort A) vs Futibatinib (Cohort B): serious adverse events | 23 of 87 | 6 of 28 | 115 | NCT04189445 | Trial comparisons |
| ARM I (HIGHER-DOSE): vs ARM II (LOWER-DOSE):: deaths from any cause | 16 of 20 | 25 of 30 | 50 | NCT03012672 | Trial comparisons |
| ARM I (HIGHER-DOSE): vs ARM II (LOWER-DOSE):: serious adverse events | 9 of 20 | 14 of 30 | 50 | NCT03012672 | Trial comparisons |
Cohort 1 vs Cohort 2: To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies. | 5 of 6 | 32 of 43 | 49 | NCT04214860 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 6 of 6 | 26 of 43 | 49 | NCT04214860 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 5 of 6 | 32 of 43 | 49 | NCT04214860 | Trial comparisons |
| Post-Chemotherapy vs Post-Transplant: deaths from any cause | 5 of 30 | 2 of 9 | 39 | NCT02756572 | Trial comparisons |
| Post-Chemotherapy vs Post-Transplant: serious adverse events | 30 of 30 | 9 of 9 | 39 | NCT02756572 | Trial comparisons |
| Arm I: 1200cGy vs Arm II: 1350cGy: deaths from any cause | 19 of 23 | 2 of 2 | 25 | NCT00540995 | Trial comparisons |
| Arm I: 1200cGy vs Arm II: 1350cGy: serious adverse events | 7 of 23 | 2 of 2 | 25 | NCT00540995 | Trial comparisons |
| Idelalisib 100mg vs Placebo Oral Tablet: Event Free Survival at One Year. | 9 of 9 | 7 of 7 | 16 | NCT03151057 | Trial comparisons |
| Idelalisib 100mg vs Placebo Oral Tablet: deaths from any cause | 2 of 9 | 0 of 7 | 16 | NCT03151057 | Trial comparisons |
Idelalisib 100mg vs Placebo Oral Tablet: Treatment-limiting Toxicities Will be Defined as Idelalisib Interruption for >14 Days, or Other >3 Adverse Events as Defined by CTCAE IV Not Captured in the Protocol for Dose De-escalation. | 9 of 9 | 7 of 7 | 16 | NCT03151057 | Trial comparisons |
| Idelalisib 100mg vs Placebo Oral Tablet: serious adverse events | 7 of 9 | 4 of 7 | 16 | NCT03151057 | Trial comparisons |
| Stratum 1: Myeloid Malignancies vs Stratum 2: ALL and MLM: deaths from any cause | 4 of 4 | 6 of 6 | 10 | NCT02419755 | Trial comparisons |
| Stratum 1: Myeloid Malignancies vs Stratum 2: ALL and MLM: serious adverse events | 1 of 4 | 2 of 6 | 10 | NCT02419755 | Trial comparisons |
Total Body Irradiation (TBI)/Cyclophosphamide (Cy) vs Thiotepa, Busulfan, and Fludarabine (TBF): Proportion of saGVHD Using a ProphylaxisRegimen With no Calcineurin Inhibitors After Day 100 Post First Allogeneic HLA-Matched Sibling or Unrelated Donor HCT for Hematological Malignancies. | 0 of 2 | 0 of 1 | 3 | NCT05579769 | Trial comparisons |
| Total Body Irradiation (TBI)/Cyclophosphamide (Cy) vs Thiotepa, Busulfan, and Fludarabine (TBF): Cumulative Incidence of Relapse | 0 of 2 | 0 of 1 | 3 | NCT05579769 | Trial comparisons |
| Total Body Irradiation (TBI)/Cyclophosphamide (Cy) vs Thiotepa, Busulfan, and Fludarabine (TBF): Cumulative Incidence of Non Relapse Mortality (NRM) | 0 of 2 | 0 of 1 | 3 | NCT05579769 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005170/comparisons